Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Cann Group Limited specializes in the end-to-end process of bringing medicinal cannabis to market. Its activities span from genetic development and cultivation to product manufacturing, clinical trials, and ultimately, the supply of therapeutic cannabis for both Australian consumption and international export. The company holds specific licenses enabling it to conduct research and grow cannabis for human medicinal and scientific study. Founded in 2014, Cann Group Limited operates out of its base in Port Melbourne, Australia.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E.